These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29844843)

  • 1. Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.
    Liu YX; Zhang KJ; Tang LL
    Oncol Lett; 2018 Jun; 15(6):10008-10016. PubMed ID: 29844843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
    Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
    Asano Y; Kashiwagi S; Onoda N; Kurata K; Morisaki T; Noda S; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Br J Cancer; 2016 Jan; 114(1):14-20. PubMed ID: 26757422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study.
    Sridhar N; Glisch C; Jawa Z; Chaudhary LN; Kamaraju S; Burfeind J; Charlson J; Chitambar CR; Jorns JM; Cheng YC
    J Cancer; 2022; 13(8):2472-2476. PubMed ID: 35711833
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).
    Mishra A; Mishra SK; Sharanappa V; Krishnani N; Kumari N; Agarwal G
    Indian J Surg Oncol; 2024 Jun; 15(2):250-257. PubMed ID: 38741650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
    Riaz N; Idress R; Habib S; Lalani EN
    Front Oncol; 2020; 10():1083. PubMed ID: 32850312
    [No Abstract]   [Full Text] [Related]  

  • 10. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy.
    Wasserman JK; Williams PA; Islam S; Robertson SJ
    Pathol Res Pract; 2016 Jun; 212(6):539-44. PubMed ID: 27067807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
    McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
    Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival.
    Yu L; Yu Q; Xu C; Wang M; Song J; Gao X
    Gland Surg; 2022 Nov; 11(11):1772-1783. PubMed ID: 36518802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
    Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
    Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
    Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.